EyePoint launches Dexycu in US

EyePoint Pharmaceuticals has commercially launched Dexycu in the U.S. for the treatment of postoperative inflammation.

Dexycu (dexamethasone intraocular suspension 9%) is administered at the end of cataract surgery and is the first FDA-approved intraocular steroid for postoperative inflammation.

Its launch will be phased, with the first phase including leading cataract surgery experts.

“There are approximately 4.8 million cataract surgeries a year in the U.S.,” Nancy Lurker, president and CEO of EyePoint, said in a press release. “Dexycu offers a single-dose, sustained-release treatment option conveniently administered at the end of cataract surgery which can eliminate the complicated and burdensome steroid eye drop regimen following surgery.”

EyePoint Pharmaceuticals has commercially launched Dexycu in the U.S. for the treatment of postoperative inflammation.

Dexycu (dexamethasone intraocular suspension 9%) is administered at the end of cataract surgery and is the first FDA-approved intraocular steroid for postoperative inflammation.

Its launch will be phased, with the first phase including leading cataract surgery experts.

“There are approximately 4.8 million cataract surgeries a year in the U.S.,” Nancy Lurker, president and CEO of EyePoint, said in a press release. “Dexycu offers a single-dose, sustained-release treatment option conveniently administered at the end of cataract surgery which can eliminate the complicated and burdensome steroid eye drop regimen following surgery.”